Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 118, Issue 3, Pages 501-555Publisher
SPRINGER
DOI: 10.1007/s11060-013-1338-5
Keywords
Adult; Chemotherapy; Cytotoxic; Glioblastoma; Mortality; Progressive; Recurrent; Relapsing; Survival; Temozolomide
Categories
Funding
- CNS
- Tumor Section of the American Association of Neurological Surgeons
Ask authors/readers for more resources
What is the impact of cytotoxic chemotherapy on disease control and survival in the adult patient with progressive glioblastoma? This recommendation applies to adults patients with progressive glioblastoma. Temozolomide is recommended as superior to procarbazine in patients with first relapse of glioblastoma after having received nitrosourea chemotherapy or no prior cytotoxic chemotherapy at the time of initial therapy. The use of BCNU-impregnated biodegradable polymer wafers is recommended in the management of progressive glioblastoma as a surgical adjunct when cytoreductive surgery is indicated, taking into account the associated toxicities seen with this modality. Consideration of a variety of cytotoxic chemotherapy agents of uncertain benefit is recommended in the setting of progressive glioblastoma based on the judgment of the treating physician taking into account the individual patients prior treatment exposure, systemic health, and likelihood of tolerance of the toxicities of any given agent. It is recommended in such cases that enrollment in available clinical trials be encouraged.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available